Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116 [MarketWatch]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: MarketWatch
Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116 Sage Therapeutics Inc. shares SAGE, +70.04% rose another 2% Friday, adding to prior-session gains of more than 70%, as SunTrust Robinson Humphrey became the latest shop to raise its stock price target after positive results in a mid-stage trial of a new depression treatment. SunTrust boosted its target to $178 from $116, and reiterated a buy rating. "Based on the positive top-line readout from the Phase II trial for SAGE-217 in MDD, we have increased the probability of success from 30% to 60%,' analyst Edward Nash wrote in a note. "Post-partum depression (PPD) is the second mood disorder being investigated by SAGE for SAGE-217. We have increased the probability of success from 50% to 60% in PPD as we believe a read-through from the positive MDD Phase II data is warranted." On Thursday, Leerink raised its stock price target to $246 from $123, while RBC raised its target to $280. Shares cl
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $17.00 to $14.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $8.00. They now have a "market perform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Truist Financial Co. from $13.00 to $8.00. They now have a "hold" rating on the stock.MarketBeat
SAGE
Earnings
- 10/29/24 - Miss
SAGE
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- SAGE's page on the SEC website